Moleculin Q1: Cash $10.3M; MIRACLE trial 40% CRc; 45 subjects enrolled

Moleculin Biotech, Inc.

Cash and equivalents $10.3M as of March 31, 2026; R&D expense $5.4M (up $2.0M YoY) on MIRACLE trial costs.
MIRACLE Phase 2B/3 trial: first 45 subjects enrolled; blinded composite complete remission (CRc) rate of 40%.
First interim unblinding expected June 2026; 90th subject recruitment targeted for Q3 2026.
Completed Q1 2026 financings with ~$8.3M gross proceeds; runway extended into Q3 2026.
Expect to start pancreatic cancer trial in 2H 2026; aiming for rolling NDA submission for R/R AML in 2028.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.